Develops a prompt, potent, predictable subcutaneous medication to treat pre-hospital heart attack (STEMI) patients, aiming to preserve heart muscle and ensure open coronary arteries on hospital arrival. Assessing a single subcutaneous injection in a pivotal Phase 3 randomized, blinded, placebo‑controlled international trial in the pre-hospital setting.